MX2024010644A - Uso de iptacopan para el tratamiento de la nefritis lupica. - Google Patents

Uso de iptacopan para el tratamiento de la nefritis lupica.

Info

Publication number
MX2024010644A
MX2024010644A MX2024010644A MX2024010644A MX2024010644A MX 2024010644 A MX2024010644 A MX 2024010644A MX 2024010644 A MX2024010644 A MX 2024010644A MX 2024010644 A MX2024010644 A MX 2024010644A MX 2024010644 A MX2024010644 A MX 2024010644A
Authority
MX
Mexico
Prior art keywords
iptacopan
lupus nephritis
treatment
hydrochloride
inhibitor
Prior art date
Application number
MX2024010644A
Other languages
English (en)
Spanish (es)
Inventor
Nicholas Webb
Janina Linnik
Matthias Meier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2024010644A publication Critical patent/MX2024010644A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024010644A 2022-03-04 2023-03-03 Uso de iptacopan para el tratamiento de la nefritis lupica. MX2024010644A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263316623P 2022-03-04 2022-03-04
PCT/IB2023/052010 WO2023166487A1 (en) 2022-03-04 2023-03-03 Use of iptacopan for the treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
MX2024010644A true MX2024010644A (es) 2024-09-06

Family

ID=85704041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010644A MX2024010644A (es) 2022-03-04 2023-03-03 Uso de iptacopan para el tratamiento de la nefritis lupica.

Country Status (10)

Country Link
US (1) US20250195492A1 (https=)
EP (1) EP4486343A1 (https=)
JP (1) JP2025507830A (https=)
KR (1) KR20240155291A (https=)
CN (1) CN118785906A (https=)
AU (1) AU2023229221A1 (https=)
CA (1) CA3248808A1 (https=)
IL (1) IL314494A (https=)
MX (1) MX2024010644A (https=)
WO (1) WO2023166487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119656165A (zh) * 2023-09-20 2025-03-21 上海美悦生物科技发展有限公司 杂环化合物在制备预防和/或治疗肾脏疾病的药物中的用途
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN120208923A (zh) 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式

Also Published As

Publication number Publication date
AU2023229221A1 (en) 2024-08-15
EP4486343A1 (en) 2025-01-08
IL314494A (en) 2024-09-01
JP2025507830A (ja) 2025-03-21
WO2023166487A1 (en) 2023-09-07
CA3248808A1 (en) 2023-09-07
US20250195492A1 (en) 2025-06-19
KR20240155291A (ko) 2024-10-28
CN118785906A (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
CR20220258A (es) Inhibidores de kras g12c
ZA202208783B (en) Kras mutant protein inhibitors
EA202193015A1 (ru) Ингибиторы cdk
PH12019500296A1 (en) Amino pyrimidine ssao inhibitors
WO2020150552A3 (en) Methods of treating cartilage disorders through inhibition of clk and dyrk
PH12021551317A1 (en) Modulators of trex1
MX2024010644A (es) Uso de iptacopan para el tratamiento de la nefritis lupica.
MX2023001071A (es) Tratamiento de la migraña.
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
WO2020051532A3 (en) Macrocyclic compounds for the treatment of medical disorders
MX2022007626A (es) Combinaciones.
MX2022007628A (es) Combinaciones.
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
PH12022550130A1 (en) Enzyme inhibitors
PH12023550153A1 (en) Inhibitors of complement factors and uses thereof
MX2021007247A (es) Derivados de rapamicina.
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
EA202092540A1 (ru) Комбинации для лечения рака
MX2023013148A (es) Iptacopan para el tratamiento del sindrome uremico hemolitico atipico.
WO2019195641A3 (en) 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same
SA522431572B1 (ar) مركب بيريميدين-5-كربوكساميد
ZA202407245B (en) Novel use of pitolisant for treating severe fatigue
WO2021102359A3 (en) Taspase1 inhibitors and uses thereof
ZA202004849B (en) Therapeutic agents for treating restless legs syndrome